Bryce Point Capital LLC Purchases Shares of 54,358 Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Bryce Point Capital LLC acquired a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 54,358 shares of the biopharmaceutical company’s stock, valued at approximately $1,134,000.

A number of other institutional investors and hedge funds also recently modified their holdings of CPRX. Steward Partners Investment Advisory LLC acquired a new position in Catalyst Pharmaceuticals during the fourth quarter worth approximately $27,000. Farther Finance Advisors LLC raised its stake in Catalyst Pharmaceuticals by 125.1% in the 4th quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company’s stock valued at $56,000 after acquiring an additional 1,495 shares during the period. Wilmington Savings Fund Society FSB acquired a new stake in Catalyst Pharmaceuticals during the 4th quarter valued at $65,000. KBC Group NV boosted its position in Catalyst Pharmaceuticals by 48.8% during the fourth quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company’s stock worth $98,000 after purchasing an additional 1,542 shares during the period. Finally, Thurston Springer Miller Herd & Titak Inc. bought a new position in Catalyst Pharmaceuticals during the fourth quarter worth $134,000. 79.22% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Bank of America restated a “buy” rating and set a $30.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. Stephens restated an “overweight” rating and set a $33.00 price objective on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. Robert W. Baird increased their target price on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an “outperform” rating in a research note on Monday, March 3rd. HC Wainwright restated a “buy” rating and issued a $35.00 price target on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. Finally, Baird R W upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Monday, February 3rd. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Catalyst Pharmaceuticals presently has an average rating of “Buy” and an average target price of $32.29.

Catalyst Pharmaceuticals Stock Performance

Shares of NASDAQ CPRX opened at $24.46 on Thursday. The stock has a market capitalization of $2.97 billion, a P/E ratio of 20.73, a PEG ratio of 3.31 and a beta of 0.79. The stock’s fifty day moving average is $22.74 and its 200 day moving average is $21.90. Catalyst Pharmaceuticals, Inc. has a 52 week low of $14.47 and a 52 week high of $26.16.

Insider Buying and Selling at Catalyst Pharmaceuticals

In related news, insider Brian Elsbernd sold 62,975 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total value of $1,447,165.50. Following the transaction, the insider now directly owns 188,564 shares of the company’s stock, valued at $4,333,200.72. This trade represents a 25.04 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Gary Ingenito sold 44,904 shares of the company’s stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total value of $991,929.36. Following the sale, the insider now owns 68,873 shares of the company’s stock, valued at $1,521,404.57. The trade was a 39.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 11.00% of the company’s stock.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.